---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-25-000037"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2025-07-24T23:59:59+00:00"
generated_at: "2026-05-18T01:57:58.599107+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# Edwards Q2 sales up 11.9% to $1.53B; raises full-year guidance

## Summary
- Q2 GAAP EPS $0.57; adjusted EPS $0.67.
- TAVR sales $1.1B (+8.9%); TMTT $134.5M (+61.9%); Surgical $267M (+7.7%).
- Full-year sales growth guidance raised to 9-10% (from 8-10%); adjusted EPS expected at high end of $2.40-$2.50.
- SAPIEN M3 CE Mark approved in Q2; 10-year PARTNER II data affirm durability.
- Q3 guidance: sales $1.46-$1.54B, adjusted EPS $0.54-$0.60.

## SEC filing metadata
- accession: 0001099800-25-000037
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2025-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000037/0001099800-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000037/ew-20250724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-25-000037
- JSON: https://secwatch.observer/filing/0001099800-25-000037.json
- Plain text: https://secwatch.observer/filing/0001099800-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.